UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): December 4, 2019

 

IMMUNIC, INC.

 (Exact name of registrant as specified in its charter)

 

Delaware 001-36201 56-2358443
(State or other jurisdiction
of incorporation)
(Commission File Number) (IRS Employer Identification No.)
     
 

1200 Avenue of the Americas, Suite 200

New York, NY 10036

USA

 
  (Address of principal executive offices)  

 

Registrant’s telephone number, including area code: 49 89 250079460

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Title of each class Trading symbol(s)

Name of each exchange

on which registered

Common Stock, $0.0001 par value IMUX The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b2 of this chapter).

 

Emerging growth company ý

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Yes ý No ¨

 

 

 

 

Item 8.01. Other Events

 

Effective December 4, 2019, the Board of Directors (the “Board”) of Immunic, Inc. changed the composition of its committees. The current membership of Board committees is as follows:

 

· Audit Committee: Barclay Phillips (Chair), Jan Van den Bossche and Jörg Neermann.

 

· Compensation Committee: Tamar Howson (Chair) and Jörg Neermann.

 

· Nominating and Governance Committee: Vincent Ossipow (Chair) and Jan Van den Bossche.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

 

             
Dated: December 6, 2019       Immunic, Inc.
       
        By:  

/s/ Daniel Vitt

            Daniel Vitt
            Chief Executive Officer

Immunic (NASDAQ:IMUX)
Historical Stock Chart
From Nov 2020 to Dec 2020 Click Here for more Immunic Charts.
Immunic (NASDAQ:IMUX)
Historical Stock Chart
From Dec 2019 to Dec 2020 Click Here for more Immunic Charts.